By Dr. Traj Nibber
(eCBome) is a broader and more appropriate term than the old endocannabinoid
system (ECS), and incorporates the more recent research into this fascinating
What is the eCBome
Briefly, eCBome is a protective,
and communication network that exists all over the body, and interacts with
hormonal, nervous, immune, endocrine, microbiome, and other systems of the
body. The eCBome plays a major role in the health of many organs of the body
including; the reproductive system in both males and females, hormonal system,
kidneys, liver, gut microbiome, heart and circulatory system, nervous system,
skin among other tissues.
The ecBome consists of
a number of molecules called endocannabinoids (eCBs) that bind to various
receptors, including cannabinoid receptors 1 and 2, plus a few others, and
enzymes that manufacture and break down the eCBs. In that regard the eCBome offers
a new target for natural health products for maintenance of good health and
optimal function of the body.
Since there are
multiple targets – the enzymes, receptors and the eCBs, it is possible to
manipulate one or more of these targets. For example, by stimulating or
inhibiting various receptors. Alternatively, one can increase the synthesis of
eCBs by providing the building blocks for the production of eCBs through the
intake of certain fatty acids like omega 3. Similarly, one can reduce the
breakdown of the eCBs by inhibiting the enzymes that breakdown the eCBs.
In this regard, P.E.A.k Relief is specifically
formulated with the view of manipulating various eCBome components to help
deliver help achieve a normal inflammatory response and relief of discomfort effectively
What is P.E.A.k Relief?
P.E.A.k Relief contains a number of natural
health ingredients that support, and optimize the functioning of the eCBome
through the use of well-defined and clinically tested ingredients that provide
multiple mechanisms of action. PEAk Relief contains the following ingredients:
- Magnesium glycinate
Let us discuss rationale
of each of these ingredients:
The herb boswellia serrata is a well-known
ayurvedic herb, found to promote a proper inflammatory response, comparable to,
and perhaps even more potent than curcumin. The ingredient is standardized to
the major actives called boswellic acids, which represent a large group, with
the key actives of keto-boswellic acids (KBA), and
alpha keto boswellic acids (AKBA) which are responsible for the analgesic
activity. P.E.A.k Relief contains both these actives in high concentrations for
a healthy inflammatory response.
Quercetin is a well-known flavonoid with
excellent antioxidant function, which readily mops up oxygen and nitrogen free
radical species that are released which further initiate cell damage, and start
the whole inflammatory process. Quercetin normalizes the inflammatory response
by a different mechanism than boswellia. Quercetin has been found to act in a synergistic
manner with a number of herbs like curcumin, green tea and resveratrol. In
addition, quercetin is effective in reducing the damage done by mast cells,
which are specific type of immune cells that are overly active during allergies
and discomfort, and which release their powerful chemicals at the site of
Magnesium in the form of glycinate is a
powerful muscle relaxant as well as being the key component in the action of
many enzymes in the body. Magnesium’s inclusion provides the much-needed
relaxation of muscles as well as assisting, and optimizing the synaptic plasticity, which is the ease
with which nerve signals move to and fro from the brain to the distant tissues.
Synaptic plasticity is compromised in many conditions besides discomfort and
muscle damage, for example the damage caused by AGE`s (advanced glycation end
products) produced when excess sugars bind with various proteins in the body (lining
of the blood vessels, enzymes, skin etc.) causing loss of function of the
proteins. Finally, magnesium in the glycinate form is a highly bioavailable,
which means it is well absorbed by the body without causing the typical gastro-intestinal
side-effects attributed to some other forms of magnesium.
PEA a molecule that is
naturally found in various food sources like alfalfa, butter, peanuts, egg
yolk, and soy. In addition, the body naturally produces PEA upon demand whenever
there is damage and danger to the cells of the tissues.
How does PEA act?
PEA is made locally,
and acts locally by the cells when tissues come under threat. PEA acts on the
eCBome (see previous blogs) through multiple mechanisms including:
- GPR55 receptor: was
originally thought of as the third cannabinoid receptor. Activation of this
receptor, like CB2 has a number of health protective effects like preventing
cholesterol plaque formation, reducing toxic LDL levels as well as protective
effects on the kidneys, brain, gastro-intestinal tract and the heart.
- PPAR-alpha receptor: activation of this receptor helps promote a healthy
inflammatory response. This is a key receptor in discomfort relief and the inflammatory
- Prevents uptake of AEA, one of the key eCBs there by prolonging its action.
- Prevents degradation of eCBs like AEA and 2-AG, the enzyme FAAH breaks down AEA, PEA acts as an
alternate dance partner for the enzyme FAAH, freeing AEA for a prolonged
- TRPV1 receptor:
another receptor, which is associated with the inflammatory response. Inhibiting
this receptor promotes a healthy inflammatory response.
cell stabilizer: mast cells contribute greatly to the
inflammatory response through the release of powerful chemicals within their
payload like histamine and various cytokines, powerful cellular signaling
molecules, which take part in the inflammatory process. Mast cells are one of
the first responders at the scene when there is damage. PEA basically makes
mast cells “chill out” and reduce their aggressive behaviour by preventing the
release of their contents.
Mechanisms 3, 4 and 5
above are often referred to as the “entourage effect”.
PEA has been a hidden
gem until now, with over 60 years of research on this fascinating molecule (see
the blog “PEA the hidden gem”) for various conditions, but especially for discomfort
and inflammatory response. In many human studies, PEA at 1200 mg daily dose
worked as effectively, but with far greater safety as some well known over the
counter drugs. One of the unique features of PEA is that it has been studied
and found effective in conditions that are resistant to treatment like lumber
compression injuries and neuropathic discomfort, which is very difficult to
This is a proprietary
ingredient of two well-studied Chinese herbs- Scutellaria Baicalensis and Senegalia catechu, which have a proven synergistic effect in
reducing discomfort and promoting a proper inflammatory response. The mechanism
of action is different and acts by inhibiting both the COX-2 and LOX enzymes,
which play a critical role in generating powerful inflammatory molecules like
prostaglandins and leukotrienes. Univestin™ inhibits
both COX1/COX-2 and 5-LO enzymatic activity with a balanced approach thereby
decreasing the metabolism of AA to prostaglandins, and leukotrienes. Univestin™
also decreases levels of the pro-inflammatory cytokines TNFα, IL-1β, and IL-6,
and the key gene expression regulators, NFκB and PPARγ, which results in
reduced Cox-2, 5-lo, TNFα,IL-1β, IL-6 but not COX-1
gene expression. Univestin™ is a potent antioxidant and acts as a metabolic
“sink” for reactive oxygen species (ROS), thereby reducing the detrimental
oxidative stress produced in the wear and tear process on joints.
PEAk Relief is a new and powerful
combination of some well-known, and a few novel ingredients, with multiple and
different mechanisms of action to give a broader relief from discomfort and promote
a healthy inflammatory response, effectively and safely.
Sampalis J and Brownell A, “Univestin Human Clinical Efficacy:
A Randomized, Double Blind, Placebo and
Active Comparator Controlled Pilot Study of UP446, a Novel Dual Pathway
Inhibitor Anti-Inflammatory Agent of Botanical Origin” Nutrition
Journal 2012, 11:21: 11-21
“Efficacy and Safety of Flavocoxid, a Novel Therapeutic, Compared with Naproxen:
A Randomized Multicenter Controlled Trial in Subjects with Osteoarthritis of
et-al, “GOAL: multicenter, open-label, post-marketing study of flavocoxid, a
novel dual pathway inhibitor anti-inflammatory agent of botanical origin”
Opinion Vol. 2010; 26: 1055–1063
et-al, “A combination of Scutellaria bacicalensis and Acacia catechu extract
for short term symptomatic relief of joint discomfort associated with
osteoarthritis of the knee” J Med Food, 2014; 17: 707-713
Keppel Hesselink JM. Autacoids: “A
New Fundament for Pain Medicine of the 21th Century. Anaesthesia. Critical Care and Pain Management”. 2016; 1:
Keppel Hesselink JM. “Evolution in
pharmacologic thinking around the natural analgesic palmitoylethanolamide: from
nonspecific resistance to PPAR-α agonist and effective nutraceutical”. J Pain
Res. 2013; 6: 625-634.
A Biasiotta, et-al. “Efficacy of
palmitoylethanolamide in patients with painful neuropathy. A clinical and
neurophysiological open study”. Preliminary effects. European Journal of Pain
Supplements. 2010; 4: 77.
Truini A et-al. “Palmitoylethanolamide
restores myelinated-fibre function in patients with chemotherapy-induced
painful neuropathy”. CNS Neurol Disord Drug Targets. 2011; 10: 916-920.
Marini I et-al. ”Palmitoylethanolamide
versus a nonsteroidal anti-inflammatory drug in the treatment of
temporomandibular joint inflammatory pain”. J Orofac Pain. 2012; 26: 99-104.
Keppel Hesselink JM. “New Targets
in Pain, Non-Neuronal Cells, and the Role of Palmitoylethanolamide”. The Open
Pain Journal. 2012; 5: 12-23.
Keppel Hessellink JM. “Palmitoylethanolamide,
a neutraceutical, in nerve compression syndromes: efficacy and safety in
sciatic pain and carpal tunnel syndrome”. J Pain Res. 2015; 8: 729-734.
Esposito E and Cuzzocrea S. “Palmitoylethanolamide
is a new possible pharmacological treatment for the inflammation associated
with trauma”. Mini Rev Med Chem. 2013; 13: 237-255.
Keppel Hesselink JM and Hekker TA. “Therapeutic utility of
palmitoylethanolamide in the treatment of neuropathic pain associated with
various pathological conditions: a case series.” J Pain Res. 2012; 5: 437-442.